Cutaneous and mucocutaneous leishmaniasis
Top Cited Papers
- 1 November 2009
- journal article
- review article
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 22 (6) , 491-502
- https://doi.org/10.1111/j.1529-8019.2009.01272.x
Abstract
Leishmaniasis is a cluster of diseases caused by protozoa in the genus Leishmania. There are three basic clinical forms: cutaneous, mucocutaneous, and visceral leishmaniasis. The present review focuses on the diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Characteristics of both the human host and the parasite species influence the clinical disease manifestations that range from asymptomatic exposure, to self-healing skin ulcers, to life-threatening widespread destructive ulcerations. Whether through medical treatment or through spontaneous resolution, skin ulcerations generally result in disfiguring scars with significant social and economic impact. Tests to confirm the diagnosis should be performed on patients who have recently visited endemic areas and have skin or mucosal manifestations consistent with leishmaniasis. Treatment depends on the species of Leishmania and the risk of widespread or disfiguring disease. Because of increasing trends in global travel, educating health care providers to recognize and treat leishmaniasis in both endemic and non-endemic countries is imperative.Keywords
This publication has 87 references indexed in Scilit:
- What determines the success or failure of intracellular cutaneous parasites? Lessons learned from leishmaniasisMedical Microbiology and Immunology, 2009
- Is Paromomycin an Effective and Safe Treatment against Cutaneous Leishmaniasis? A Meta-Analysis of 14 Randomized Controlled TrialsPLoS Neglected Tropical Diseases, 2009
- Treatment of acute Old World cutaneous leishmaniasis: A systematic review of the randomized controlled trialsJournal of the American Academy of Dermatology, 2007
- Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugsZeitschrift Fur Parasitenkunde-Parasitology Research, 2007
- Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensisJournal of the American Academy of Dermatology, 2007
- Advances in leishmaniasisPublished by Elsevier ,2005
- Randomized, Double-Blind Clinical Trial of Topical Imiquimod 5% with Parenteral Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis in PeruClinical Infectious Diseases, 2005
- Cutaneous New World leishmaniasis-sporotrichosis coinfection: Report of 3 casesJournal of the American Academy of Dermatology, 1999
- LeishmaniasisJournal of the American Academy of Dermatology, 1996
- Specific Inhibition of Lymphocyte-Proliferation Responses by Adherent Suppressor Cells in Diffuse Cutaneous LeishmaniasisNew England Journal of Medicine, 1982